Leonard Kruimer

Leonard Kruimer is the current Chairman at BioInvent International. Leonard has also previously served as the Chief Financial Officer at SkylineDx B.V., and as a Managing Board Member and CFO at Crucell.

Kruimer began their career in finance, working for various companies in Europe. In 1998, they joined Crucell, a biotech company that developed new treatments for devastating brain diseases. Leonard served on the company's management board and was responsible for the company's finances.

In 2012, Kruimer left Crucell and joined to-BBB, a privately held biotech company that was developing new treatments for brain diseases. Leonard was mandated to focus the company's R&D efforts and prepare it for a public offering. Leonard restructured the management board and recruited a new management team. Leonard also restructured the organization and downsized the research programs. The company was successfully able to finance a €10 million C round in May 2014. However, existing investors were not willing to finance further clinical development, leading to the liquidation of the company in 2015.

After leaving to-BBB, Kruimer joined BioInvent International AB as Chairman in 2016. Leonard then became the Chief Financial Officer at SkylineDx B.V. in August 2015, before taking on their current role as Chairman at BioInvent International in 2016.

Leonard Kruimer has a Master of Business Administration (M.B.A.) from Harvard Business School, a Bachelor of Business Administration (BBA) from the Isenberg School of Management at UMass Amherst, and a high school diploma from Peter Stuyvesant College in Curacao, Neth Antilles. Leonard is also a Certified Public Accountant (CPA) from the University of the State of New York and is certified by the AICPA in New York State.